Skip to main content

Advertisement

Log in

Response to zolendronic acid in children with type III osteogenesis imperfecta

Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Osteogenesis imperfecta (OI) is a common genetic disorder that manifests with intrauterine or pre- or postnatal fractures, blue sclera, and deafness. Various treatments for the management of OI have been tried, of which bisphosphonates (BPs) seem to have the maximum benefit in reducing fracture rate and improving bone density. Zolendronic acid is a newer BP tried for several bone diseases, mainly in adults. The objective of our analysis was to study the response to zolendronic acid in children with type III OI. The case records of subjects with type III OI receiving zolendronic acid in the past 3 years between February 2006 and March 2009 were analyzed. Relevant details were recorded on a predesigned chart. Subjective improvement, reduction in number of fractures, and the DEXA scan Z-score were used to judge improvement. Five OI type III cases were followed up in the Genetic clinic. Presentation was from neonatal period to 7 years of age; M:F ratio was 3:2. Average duration of therapy given was 20.4 months. Improvement was noted in all patients, in the form of reduction in frequency of fractures (P = 0.002) and increase in bone density on DEXA scan (P = 0.01). Side effects noted were flu-like symptoms and myalgia. No clinical problems due to hypocalcemia were noted in any of the patients. Thus, zolendronic acid is seen as a safe and effective BP in type III OI children. The exact dose for optimal benefit is yet to be determined. The long-term effects of newer BPs need further long-term trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Romero R, Pilu GL, Jeanty P (1988) Prenatal diagnosis of congenital anomalies. Appleton & Lange, Norwalk

    Google Scholar 

  2. Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377–1385

    Article  CAS  PubMed  Google Scholar 

  3. Plotkin H, Primorac D, Rowe D (2003) Osteogenesis imperfecta. In: Glorieux FH, Pettifor J, Jueppner H (eds) Pediatric bone. Academic Press, San Diego, pp 443–471

    Chapter  Google Scholar 

  4. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952

    Article  CAS  PubMed  Google Scholar 

  5. Di Meglio LA, Peacock M (2006) Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21:132–140

    Article  Google Scholar 

  6. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U et al (2002) Intravenous zolendronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661

    Article  CAS  PubMed  Google Scholar 

  7. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908

    Google Scholar 

  8. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193–201

    Google Scholar 

  9. Rauch F, Glorieux FH (2005) Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med 37:295–302

    Article  CAS  PubMed  Google Scholar 

  10. Sykes B, Ogilvie D, Wordsworth P, Wallis G, Mathew C, Beightn P, Nicolls A, Pope FM, Thompson E, Tsipouras P, Schwartz R, Jensson O, Arnason A, Børresen AL, Heiberg A, Frey D, Steinmann B (1990) Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet 46:293–307

    Google Scholar 

  11. Glorieux FH, Travers R, Chabot G, Lanoue G (1994) Bone histomorphometric analysis in osteogenesis imperfecta. J Bone Miner Res 9:S226 (abstract)

    Google Scholar 

  12. Brown JJ, Zacharin MR (2009) Safety and efficacy of intravenous zolendronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab 22:55–63

    CAS  PubMed  Google Scholar 

  13. Li EC, Davis LE (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25:2669–2708

    Article  CAS  PubMed  Google Scholar 

  14. Plotkin H, Nunez M, Alvarez Filgueira ML, Zanchetta JR (1996) Lumbar spine bone density in Argentine children. Calcif Tissue Int 58:144–149

    CAS  PubMed  Google Scholar 

  15. Davie MW, Haddaway MJ (1994) Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child 70:331–334

    Article  CAS  PubMed  Google Scholar 

  16. Reinus WR, McAlister WH, Schranck F, Chines A, Whyte MP (1998) Differing lumbar vertebral mineralization rates in ambulatory pediatric patients with osteogenesis imperfecta. Calcif Tissue Int 62:17–20

    Article  CAS  PubMed  Google Scholar 

  17. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J (1992) Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int 50:36–41

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Inusha Panigrahi.

About this article

Cite this article

Panigrahi, I., Das, R.R., Sharda, S. et al. Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab 28, 451–455 (2010). https://doi.org/10.1007/s00774-009-0149-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-009-0149-4

Keywords

Navigation